» Articles » PMID: 11351137

The Cerebrospinal Fluid Levels of Tau, Growth-associated Protein-43 and Soluble Amyloid Precursor Protein Correlate in Alzheimer's Disease, Reflecting a Common Pathophysiological Process

Overview
Publisher Karger
Date 2001 May 15
PMID 11351137
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Cerebrospinal fluid (CSF) levels of tau (total tau), growth-associated protein-43 (GAP-43), soluble amyloid precursor protein (sAPP; i.e. total sAPP), and beta-amyloid(42) (Abeta(42)) were studied in patients with frontotemporal dementia (FTD; n = 14), Alzheimer's disease (AD; n = 47) and vascular dementia (VAD; n = 16), and in age-matched controls (n = 12). CSF-tau was increased in AD compared to controls and FTD (p < 0.001 for both). CSF-GAP-43 was increased in AD compared to controls (p < 0.05), and both CSF-GAP-43 and CSF-sAPP were increased in AD compared to FTD (p < 0.01). Positive and highly significant correlations were found between CSF-tau and CSF-GAP-43 in all groups and between CSF-tau, CSF-GAP-43 and CSF-sAPP in AD. The correlations found may reflect a common pathophysiologic process such as axonal degeneration.

Citing Articles

Growth-Associated Protein 43 Levels in the Cerebrospinal Fluid Correspond to the Cerebral Blood Flow Alterations in Alzheimer's Dementia Continuum: An Original Study.

Songhori N, Goushky M, Khaleghi M, Mojerloo M, Sadeghi M, Mozafar M Health Sci Rep. 2025; 8(3):e70534.

PMID: 40078900 PMC: 11896815. DOI: 10.1002/hsr2.70534.


Addressing inter individual variability in CSF levels of brain derived proteins across neurodegenerative diseases.

Mravinacova S, Bergstrom S, Olofsson J, de San Jose N, Anderl-Straub S, Diehl-Schmid J Sci Rep. 2025; 15(1):668.

PMID: 39753643 PMC: 11698900. DOI: 10.1038/s41598-024-83281-y.


Altered brain connectivity in mild cognitive impairment is linked to elevated tau and phosphorylated tau, but not to GAP-43 and Amyloid-β measurements: a resting-state fMRI study.

Sadeghi M, Azargoonjahromi A, Nasiri H, Yaghoobi A, Sadeghi M, Chavoshi S Mol Brain. 2024; 17(1):60.

PMID: 39215335 PMC: 11363600. DOI: 10.1186/s13041-024-01136-z.


Lysosomal and synaptic dysfunction markers in longitudinal cerebrospinal fluid of de novo Parkinson's disease.

Bartl M, Nilsson J, Dakna M, Weber S, Schade S, Xylaki M NPJ Parkinsons Dis. 2024; 10(1):102.

PMID: 38760408 PMC: 11101466. DOI: 10.1038/s41531-024-00714-1.


Plasma extracellular vesicle synaptic proteins as biomarkers of clinical progression in patients with Parkinson's disease.

Hong C, Chung C, Yu R, Chan L Elife. 2024; 12.

PMID: 38483306 PMC: 10939498. DOI: 10.7554/eLife.87501.